NASDAQ:AEZS - AEterna Zentaris Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.14 +0.02 (+0.94 %)
(As of 06/18/2018 06:00 AM ET)
Previous Close$2.14
Today's Range$2.08 - $2.15
52-Week Range$0.89 - $3.29
Volume101,852 shs
Average Volume318,904 shs
Market Capitalization$35.18 million
P/E RatioN/A
Dividend YieldN/A
Beta0.98

About AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris logoAeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. It also has a collaboration agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for the development, manufacture, and commercialization of Zoptrex, which has completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer in the People's Republic of China. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.

Receive AEZS News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AEZS
CUSIPN/A
Phone843-900-3223

Debt

Debt-to-Equity RatioN/A
Current Ratio3.68
Quick Ratio3.53

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$920,000.00
Price / Sales38.24
Cash FlowN/A
Price / CashN/A
Book Value($0.17) per share
Price / Book-12.59

Profitability

EPS (Most Recent Fiscal Year)($1.35)
Net Income$-16,790,000.00
Net Margins6.95%
Return on Equity-106.80%
Return on Assets-11.42%

Miscellaneous

Employees34
Outstanding Shares16,440,000

AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

How were AEterna Zentaris' earnings last quarter?

AEterna Zentaris Inc. (NASDAQ:AEZS) announced its earnings results on Monday, May, 7th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.96. The biopharmaceutical company earned $24.66 million during the quarter, compared to analyst estimates of $2 million. AEterna Zentaris had a net margin of 6.95% and a negative return on equity of 106.80%. View AEterna Zentaris' Earnings History.

When is AEterna Zentaris' next earnings date?

AEterna Zentaris is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for AEterna Zentaris.

What price target have analysts set for AEZS?

2 brokerages have issued 12 month target prices for AEterna Zentaris' stock. Their predictions range from $3.00 to $4.00. On average, they expect AEterna Zentaris' share price to reach $3.50 in the next year. View Analyst Ratings for AEterna Zentaris.

Who are some of AEterna Zentaris' key competitors?

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the folowing people:
  • Mr. Michael V. Ward, Pres & CEO (Age 61)
  • Mr. James Clavijo, CFO & Sec. (Age 52)
  • Mr. Paul Burroughs, Director of Communications
  • Dr. Nicola Ammer, Chief Medical Officer & VP of Clinical Devel.
  • Mr. Brian Garrison, Sr. VP of Global Commercial Operations

Has AEterna Zentaris been receiving favorable news coverage?

Press coverage about AEZS stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AEterna Zentaris earned a media sentiment score of 0.15 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.31 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of AEterna Zentaris?

Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $2.14.

How big of a company is AEterna Zentaris?

AEterna Zentaris has a market capitalization of $35.18 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-16,790,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. AEterna Zentaris employs 34 workers across the globe.

How can I contact AEterna Zentaris?

AEterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 843-900-3223 or via email at [email protected]


MarketBeat Community Rating for AEterna Zentaris (AEZS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  497
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.